Tigapotide

Drug Profile

Tigapotide

Alternative Names: PCK 3145 Peptide Therapeutic Program; PCK-3145

Latest Information Update: 09 Jul 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambrilia Biopharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Gelatinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Jul 2013 No development reported - Phase-II for Prostate cancer in Canada (IV)
  • 09 Jul 2013 No development reported - Phase-II for Prostate cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top